Last reviewed · How we verify
NCT04819178: RESGUE1
Real Life Evaluation of SGLT2 Use in Type 1 Diabetes
trial in Diabetic Ketoacidosis. Withdrawn.
1 December 2021
Quick facts
| Lead sponsor | Steno Diabetes Center Copenhagen |
|---|---|
| Status | Withdrawn |
| Study type | OBSERVATIONAL |
| Start date | 1 June 2021 |
| Primary completion | 1 December 2021 |
| Estimated completion | 1 December 2021 |
| Sites | 3 locations across Denmark |
Conditions studied
- Diabetic Ketoacidosis — all drugs for Diabetic Ketoacidosis →
Sponsor
Steno Diabetes Center Copenhagen — full company profile →
Who can join
Adults 18 to 90, any sex, with Diabetic Ketoacidosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary aim of the study is to prospectively monitor the risk of diabetic ketoacidosis (DKA) during treatment with sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 1 diabetes after the treatment has become available as an adjunct therapy for people with type 1 diabetes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04819178
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetic Ketoacidosis
Currently open trials in the same condition.
- NCT07167693 — Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes · Phase 1, PHASE2 · recruiting
- NCT07127406 — Postoperative Euglycemic Ketoacidosis Frequency in Sodium-Glucose Cotransporter-2 Inhibitor Users · active not recruiting
- NCT06955416 — REAMBERIN® 1.5% in Rehydration Therapy of Diabetic Ketoacidosis · Phase 2, PHASE3 · recruiting
- NCT07193069 — Clinical and Biological Signs of Dapagliflozin Overdose in ICU Patients With Metformin Poisoning · recruiting
Other Steno Diabetes Center Copenhagen trials
Trials by the same sponsor.
- NCT07485075 — Digital Support for Reducing Salt Intake Among Patients With Diabetic Kidney Disease: Protocol for a Controlled Clinical · NA · recruiting
- NCT07427251 — The Postprandial Hypo-Avoid Study · Phase 4 · not yet recruiting
- NCT06954090 — Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study · Phase 4 · enrolling by invitation
- NCT06832059 — Precision Nutrition Versus Standard Dietary Care: Continuous Glucose Monitoring as a Tool for Guided Nutrition Care in T · NA · recruiting
- NCT07377266 — The Impact of Changing to a New Child- and Family-centered Outpatient Diabetes Clinic Focusing on Early Involvement of t · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04819178 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Steno Diabetes Center Copenhagen
- Last refreshed: 28 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04819178.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing